ArticleJournal of scleroderma and related disorders2021
Overall mortality.
Article in Journal of scleroderma and related disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Available Biomarkers for Personalized Prognostication in Early and Very Early Systemic Sclerosis: A Narrative Review of the Current Literature.Journal of personalized medicine · 2026Review
- Change in Antinuclear Antibodies After Lung Transplantation in Patients with Systemic Sclerosis.Journal of clinical medicine · 2025Article
- Racial and ethnic associations with interstitial lung disease and healthcare utilization in patients with systemic sclerosis.Rheumatology (Oxford, England) · 2025Article
- Biological hallmarks of systemic sclerosis are present in the skin and serum of patients with Very Early Diagnosis of Systemic Sclerosis (VEDOSS).Rheumatology (Oxford, England) · 2025Article
- Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years.Rheumatology international · 2024Review
- Untangling the relationship between smoking and systemic sclerosis: an analysis of the EUSTAR cohort.RMD open · 2024Article
- Deficiency and altered phenotype of mucosal-associated invariant T cells in systemic sclerosis.Journal of scleroderma and related disorders · 2024Article
- Outcomes in systemic sclerosis patients hospitalized with COVID-19: Insight from the National Inpatient Sample.Journal of scleroderma and related disorders · 2024Article
- Digital Ulcers and Ventricular Arrhythmias as Red Flags to Predict Replacement Myocardial Fibrosis in Systemic Sclerosis.Journal of clinical medicine · 2023Article
- Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases.Advances in therapy · 2022Article
- Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition.Journal of scleroderma and related disorders · 2022Article
- Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates.Diagnostics (Basel, Switzerland) · 2021Article
- Impact of Covid-19 on clinical care and lived experience of systemic sclerosis: An international survey from EURORDIS-Rare Diseases Europe.Journal of scleroderma and related disorders · 2021Article
- The Relationship between Pulmonary Damage and Peripheral Vascular Manifestations in Systemic Sclerosis Patients.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Treatment of Lung Involvement in Systemic Sclerosis.Pharmaceuticals (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis is a highly morbid, complex autoimmune disease that is variable both in its phenotype and the attendant mortality driven by such manifestations. This review article synthesizes mortality data from the best available meta-analyses, subgroup analyses of single cohorts, and subjective comparisons of individual cohort studies, which in aggregate suggest that mortality in systemic sclerosis has been gradually improving over the past several decades. This review also summarizes the literature describing various risk factors for mortality in systemic sclerosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.